drugset / Trial / NCT06531798

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

NCT06531798

Phase 4 Recruiting 150 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.

Timeline

Start
2025-12-19
Primary completion
2026-10-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Formoterol Other / unclassified 5 ug Inhaled
Subject Glycopyrrolate Small molecule 7.2 ug Inhaled